Quantcast
Last updated on April 18, 2014 at 15:01 EDT

Latest Avastin Stories

2009-12-07 08:00:00

WALTHAM, Mass., Dec. 7 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite its dominance in early lines of metastatic colorectal cancer treatment, Roche/Chugai's Avastin will face increasing competition from Bristol-Myers Squibb/Eli Lilly/Merck KGaA's Erbitux in Germany, France and Spain. The new Special European Physician & Payer Forum report entitled Metastatic Colorectal Cancer in...

2009-11-17 12:22:08

NewYork-Presbyterian/Weill Cornell study opens blood-brain barrier to deliver high-dose chemotherapy to malignant brain tumors; may avoid common side effects of systemic chemotherapy Neurosurgeons from NewYork-Presbyterian Hospital/Weill Cornell Medical Center performed the world's first intra-arterial cerebral infusion of Avastin (bevacizumab) directly into a patient's malignant brain tumor. This novel intra-arterial (IA) technique may expose the cancer to higher doses of the drug therapy,...

2009-10-10 07:50:30

Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD). The study, which appears currently on-line in the American Journal of Ophthalmology, is the first to report early outcomes of a prospective, double-masked, randomized, controlled trial...

2009-09-28 08:41:00

WALTHAM, Mass., Sept. 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Roche/Chugai's Avastin is prescribed by the majority of surveyed oncologists for glioblastoma multiforme, non-small-cell lung cancer and breast cancer. Additionally, the drug is prescribed by all surveyed oncologists for colorectal cancer. However, the high cost of Avastin remains a barrier to treatment for nearly...

2009-09-07 13:50:38

U.S. researchers say the drug Avastin may improve the survival rates for recurrent glioblastomas -- the most aggressive type of primary brain tumor. Senior author Dr. Timothy Cloughesy, director of the Neuro-Oncology Program at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center says the drug helped improve survival rates in the case of glioblastomas that had recurred so dramatically, the U.S. Food and Drug Administration accelerated approval of this use of the...

2009-09-02 23:45:00

The targeted therapy Avastin, alone and in combination with the chemotherapy drug CPT-11, significantly increased response rates, progression-free survival times and survival rates in patients with a deadly form of brain cancer that had recurred. Patients with recurrent glioblastoma have a grim prognosis, and conventional treatments were typically limited to largely ineffective and highly toxic chemotherapies. Only about 5 percent of patients respond to further treatment "“ meaning...

2009-08-03 07:12:29

UCLA researchers have uncovered a new way to scan brain tumors and predict which ones will shrink when treated by the drug Avastin -- before the patient ever starts treatment. By linking high water movement in tumors to positive drug response, the UCLA team predicted with 70 percent accuracy which patients' tumors were the least likely to grow six months after therapy. Bronnie McNabb, 57, considers himself a lucky man. When his aggressive brain cancer returned after chemotherapy and...

8ebce1b9386aa8f5713297d017f504641
2009-07-30 09:30:00

UCLA researchers have uncovered a new way to scan brain tumors and predict which ones will be shrunk by the drug Avastin -- before the patient ever starts treatment. By linking high water movement in tumors to positive drug response, the UCLA team predicted with 70 percent accuracy which patients' tumors were the least likely to grow six months after therapy.Bronnie McNabb, 57, considers himself lucky. When his aggressive brain cancer returned after chemotherapy and radiation, his UCLA doctor...

e3ee029267b363ee362c969a267b606c1
2009-05-31 09:25:00

The mixture of two anti-cancer medications, along with chemotherapy, can gradually halt advanced non-small cell lung cancer, says a new study released on Saturday. Patients given Tarceva, made by the Swiss manufacturer Roche, and Avastin, saw their cancer growth halt more than a different group given just Avastin. 750 patients were randomly selected and given either Avastin and a placebo, or Avastin and Tarceva. The Tarceva group lived about 4.8 months before the cancer grew again,...

2009-05-11 09:32:06

The U.S. Food and Drug Administration has approved Avastin (bevacizumab) to treat patients with glioblastoma multiforme -- a form of brain cancer. GBM is a rapidly progressing cancer that invades brain tissue and can impact physical activities and mental abilities, the FDA said. It affects about 6,700 persons in the United States every year. Following initial treatment with surgery, radiation, and/or chemotherapy, the cancer nearly always returns, the agency said. This type of cancer is very...